MEDHINI is a generative AI-powered software platform that provides genomics-based multimodal solutions for healthcare diagnostics, focusing on areas such as antimicrobial resistance and virtual clinical trials. The platform enhances diagnostic accuracy and accessibility in pulmonology, neurology, nephrology, cardiology, and oncology, addressing the need for affordable healthcare solutions with measurable social impact.
Funding
$27.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many healthcare facilities, especially in underserved communities, lack access to advanced diagnostic tools, leading to delayed or inaccurate diagnoses. Traditional diagnostic methods can be costly, time-consuming, and require specialized expertise, limiting their accessibility and hindering timely patient care.
Solution
MEDHINI is a generative AI-powered software platform that provides genomics-based multimodal solutions for healthcare diagnostics, enhancing diagnostic accuracy and accessibility across various medical specialties. The platform integrates with existing medical machinery to provide clinical decision support, enabling quicker diagnoses, personalized treatments, and improved patient outcomes. MEDHINI's AI-driven solutions cater to hospitals, labs, bio-pharma companies, and insurance providers, offering in-silico virtual clinical trials, predictive analysis, and streamlined medical policy underwriting. By leveraging AI and genomics, MEDHINI aims to make technology-led healthcare accessible to all, creating equitable, accurate, and affordable solutions.
Target Audience
MEDHINI primarily serves hospitals, laboratories, bio-pharma companies, insurance providers, CSR initiatives, and government projects, with a focus on underserved communities, rural areas, and other vulnerable populations.
Features
- AI-powered diagnosis of 72+ pulmonology diseases, 75+ neurology diseases, 76+ nephrology and cardiology diseases, and 75+ oncology diseases using X-rays, CT scans, ultrasounds, and other inputs
- Predictive triage for 345+ diseases over a 5-year span based on current stage prognosis and diagnosis triage
- Integration with radiology/imaging, pathology/liquid serum, and genetics/FISH mutation machines for direct data input
- In-silico virtual clinical trials, BA/BE clinical trials, and AMR analysis frameworks for clinical data integration and biomarker analysis
- Medical policy underwriting/medical claim settlements/medical policy personalization through integration with decision support systems
- Climate change impact analysis on human health via the MedhxClimaQ framework
- Non-invasive Neura Chip platform (MedhxNeuCz) for self-diagnosing capabilities